Neurology · Aurora, CO
Neurology studies in Aurora, CO
32 recruiting studies have a site in Aurora.
32 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Aurora, CO + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Aurora, CO + 24 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Aurora, CO + 35 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Aurora, CO + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Aurora, CO + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Aurora, CO + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Aurora, CO + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals
- Location
- Aurora, CO + 9 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Aurora, CO + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia
- Location
- Aurora, CO + 17 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Aurora, CO + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Aurora, CO + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Aurora, CO + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Aurora, CO + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Aurora, CO + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Aurora, CO + 13 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Aurora, CO + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
- Location
- Aurora, CO + 33 other US sites
- Eligibility basics
- Ages 45–75
- RecruitingPhase 3
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
Praxis Precision Medicines
- Location
- Aurora, CO + 5 other US sites
- Eligibility basics
- Ages 0 mo–18
- RecruitingPhase 3
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics
- Location
- Aurora, CO + 34 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Use of CereGate Therapy for Freezing of Gait in PD
CereGate Inc.
- Location
- Aurora, CO + 6 other US sites
- Eligibility basics
- Ages 21–80
- RecruitingPhase 1/Phase 2
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Neurona Therapeutics
- Location
- Aurora, CO + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteers
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
Michael Shy
- Location
- Aurora, CO + 17 other US sites
- Eligibility basics
- Any age listed
- RecruitingHealthy volunteers
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
University of Iowa
- Location
- Aurora, CO + 17 other US sites
- Eligibility basics
- Any age listed
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.